Therapeutic Asset Intelligence
Evaluate emerging oncology assets and explore their scientific and development potential.
AI-Powered Oncology Asset Intelligence
Advancing the Future of Cancer Therapeutics Through AI
NeoZenome is developing an AI-powered platform to accelerate oncology drug discovery, identify promising therapeutic opportunities, and support smarter drug development decisions.
By bridging cancer biology, biomedical data, and artificial intelligence, we aim to transform complex scientific information into actionable insights that advance precision oncology.
Intelligent Discovery. Precision Development. Better Cancer Therapies.
The platform
An Intelligent Platform for Oncology Innovation
NeoZenome is building an integrated AI-powered platform designed to support therapeutic discovery, asset intelligence, and data-driven oncology development.
Our platform brings together scientific knowledge and advanced computational capabilities to help identify, evaluate, and prioritize promising opportunities across the oncology drug development landscape.
AI-Driven Discovery
Leverage intelligent computational approaches to uncover promising therapeutic opportunities and support research prioritization.
Precision Oncology Insights
Explore connections between cancer biology, therapeutic strategies, and molecularly defined patient populations.
Development Intelligence
Support informed decisions throughout early-stage therapeutic development, from initial evaluation to clinical strategy.
How it works
From Scientific Complexity to Actionable Intelligence
NeoZenome is designed to simplify complex oncology research and support evidence-informed drug development decisions.
01
Integrate
Connect diverse scientific and biomedical information within a unified intelligence environment.
02
Analyze
Apply AI-enabled analytical capabilities to explore therapeutic opportunities, biological relationships, and development considerations.
03
Evaluate
Assess emerging oncology assets and potential development opportunities through an integrated scientific perspective.
04
Advance
Translate insights into research priorities, therapeutic development strategies, and opportunities for further investigation.
Connecting knowledge, intelligence, and innovation to accelerate oncology discovery.
Built for oncology
Focused on the Next Generation of Precision Cancer Therapeutics
Cancer treatment continues to evolve through advances in molecular biology, targeted therapies, and precision medicine. Yet identifying the most promising therapeutic opportunities remains a complex challenge.
NeoZenome is developing AI-powered capabilities to support oncology innovation by connecting therapeutic discovery with biological and clinical insights.
Our initial focus is oncology, with a vision to expand the impact of AI-driven therapeutic intelligence across cancer research and development.
Targeted Therapeutics
Explore emerging therapeutic approaches and opportunities across molecularly defined cancers.
Biomarker Intelligence
Support the identification and evaluation of biomarkers relevant to therapeutic development and precision oncology.
Therapeutic Response and Resistance
Advance research into factors influencing treatment response and the development of resistance.
New Therapeutic Opportunities
Explore potential opportunities for existing and emerging oncology assets across different cancer contexts.
Clinical Development Insights
Support evidence-informed evaluation of therapeutic strategies and development opportunities.
What we believe
The right treatment for the right patient, found earlier.
Cancer is not one disease, and no single drug works for everyone. We believe drug development should be guided by who a treatment helps most.
Right patient, right drug
A drug should be judged by who it helps most, not only by whether it works on average.
Biology leads
The genetic drivers of a patient’s cancer should guide how treatments are chosen and developed.
Patients shouldn’t carry the burden of discovery
We should learn as much as we can before treatment begins, so fewer people receive therapies that can’t help them.
Rigor over hype
Computational insight should guide decisions, not replace clinical testing.
Fewer promising drugs overlooked. Fewer patients on treatments that can’t help them.
Responsible AI
Building Intelligence on Scientific Integrity
At NeoZenome, we believe that meaningful advances in oncology AI require scientific rigor, responsible technology development, and careful stewardship of research information.
Evidence-Informed Insights
Our approach emphasizes scientific evidence and transparent interpretation of research findings.
Responsible AI Development
We are committed to developing AI technologies with attention to reliability, appropriate validation, and responsible use.
Data Stewardship
We recognize the importance of protecting sensitive research information and respecting data ownership.
Scientific Collaboration
We aim to support collaboration between researchers, technology innovators, and therapeutic development partners.
Scientific integrity and responsible innovation are central to NeoZenome’s development philosophy.
About NeoZenome
Where Cancer Biology Meets Artificial Intelligence
NeoZenome is an emerging biotechnology technology company focused on advancing oncology innovation through artificial intelligence and scientific intelligence.
Our vision is to create a next-generation platform that supports the discovery, evaluation, and development of promising cancer therapeutics.
By combining translational oncology expertise with computational innovation, we seek to bridge the gap between scientific discoveries and therapeutic development opportunities.
NeoZenome was founded by a translational cancer scientist who has spent years studying why cancers respond to treatment, and why they stop responding.
Our Mission
To help more patients receive the right cancer treatment by using AI-powered scientific intelligence to find promising therapies earlier and understand who they work for.
Our Vision
To help shape a future in which intelligent technologies enable more effective, precise, and efficient cancer drug development.
Partnerships
Collaborating to Advance Oncology Innovation
NeoZenome welcomes opportunities to engage with biotechnology companies, pharmaceutical organizations, academic researchers, and technology partners interested in advancing oncology discovery and therapeutic development.
We believe collaboration across scientific and technology disciplines can accelerate innovation and create new opportunities for cancer research.
Explore Collaboration OpportunitiesDiscover What’s Next With NeoZenome
We are developing the next generation of AI-powered oncology asset intelligence.
Join our updates to learn about platform developments, future demonstrations, and collaboration opportunities.
Platform capabilities are under development. Information presented on this website describes our technology vision and planned applications.